Check-Cap Ltd. (CHEK)
- Previous Close
2.3000 - Open
2.2600 - Bid --
- Ask --
- Day's Range
2.2100 - 2.3000 - 52 Week Range
1.2700 - 4.6250 - Volume
28,183 - Avg. Volume
261,727 - Market Cap (intraday)
13.219M - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0100 - Earnings Date Apr 19, 2024 - Apr 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. Check-Cap Ltd. was incorporated in 2004 and is based in Isfiya, Israel.
www.check-cap.com85
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: CHEK
Performance Overview: CHEK
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHEK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHEK
Valuation Measures
Market Cap
13.22M
Enterprise Value
-14.82M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.89
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.62%
Return on Equity (ttm)
-48.74%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-17.62M
Diluted EPS (ttm)
-3.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
28.07M
Total Debt/Equity (mrq)
0.11%
Levered Free Cash Flow (ttm)
-12.62M
Research Analysis: CHEK
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell